Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 5.92%50.24B | 5.12%12.54B | 6.82%13.45B | 6.12%12.43B | 5.54%11.82B | 4.67%47.43B | 4.50%11.93B | 2.93%12.59B | 4.90%11.71B | 6.65%11.2B |
Cost of revenue | 2.27%37.67B | -4.31%9.2B | 2.39%10.08B | 4.26%9.39B | 7.57%9B | 7.85%36.84B | 13.28%9.62B | 7.08%9.84B | 5.74%9B | 5.21%8.37B |
Gross profit | 18.59%12.57B | 44.39%3.34B | 22.69%3.37B | 12.32%3.04B | -0.44%2.82B | -5.05%10.6B | -20.99%2.31B | -9.60%2.75B | 2.19%2.71B | 11.15%2.83B |
Operating expense | 3.32%10.86B | 12.33%2.94B | 1.60%2.64B | 0.79%2.6B | -1.33%2.68B | -0.87%10.51B | -5.47%2.62B | -2.57%2.59B | 3.07%2.58B | 1.91%2.71B |
Operating profit | 1,820.91%1.71B | 226.81%392.87M | 380.19%735M | 242.92%441.76M | 20.17%140.55M | -84.11%89.03M | -303.36%-309.82M | -59.34%153.07M | -12.68%128.82M | 200.65%116.96M |
Net non-operating interest income (expenses) | -36.91%-26.42M | -775.20%-3.35M | -112.43%-7.76M | 2.04%-7.62M | -2.75%-7.69M | 30.74%-19.3M | 94.13%-383K | 48.82%-3.65M | -4.80%-7.78M | -10.40%-7.48M |
Non-operating interest income | -57.26%5.11M | -42.41%4.52M | -94.85%197K | 19.38%191K | 56.15%203K | 219.30%11.96M | 255.13%7.85M | 359.38%3.82M | -64.60%160K | -48.41%130K |
Non-operating interest expense | 0.87%31.53M | -4.38%7.87M | 6.44%7.96M | -1.61%7.81M | 3.66%7.89M | -1.10%31.26M | -5.76%8.24M | -6.19%7.47M | 0.81%7.94M | 8.29%7.61M |
Net investment income | -9.61%331.66M | 17.42%69.7M | -23.74%121.31M | -15.89%76.04M | 11.20%64.61M | 272.89%366.93M | 200.66%59.36M | 307.80%159.07M | 360.16%90.4M | 190.39%58.1M |
Gain(Loss) on financial instruments designated as cash flow hedges | 264.93%138.79M | 1,094.35%106.97M | 53.99%-168.48M | -62.10%33.35M | -18.47%166.95M | -157.96%-84.15M | -110.51%-10.76M | -1,015.43%-366.15M | 461.93%88M | 1,700.44%204.76M |
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | 0 | -77.49%4.56M | 1,154.47%7.44M | -104.53%-919K | ||||
Income from associates and other participating interests | 9.66%104.69M | 11.55%42.71M | 20.62%10.48M | -14.91%29.79M | 61.01%21.71M | 19.41%95.47M | -15.94%38.29M | 335.44%8.69M | 72.95%35.01M | 10.88%13.48M |
Special income (charges) | -445.86%-28.66M | -413.27%-30.24M | -116.88%-690K | 215.60%415K | -82.21%1.86M | -78.92%8.29M | -179.26%-5.89M | 967.94%4.09M | -109.33%-359K | -63.33%10.45M |
Less:Other special charges | 76.85%-1.92M | -105.67%-334K | 116.88%690K | -215.60%-415K | 82.21%-1.86M | 78.92%-8.29M | 179.26%5.89M | -967.94%-4.09M | 109.33%359K | 63.33%-10.45M |
Less:Write off | --30.58M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | -24.21%7.78M | 113.21%740K | -97.56%150K | -119.85%-601K | 12.03%7.5M | -73.99%10.27M | -595.66%-5.6M | -79.31%6.15M | -32.68%3.03M | 62.34%6.69M |
Income before tax | 375.06%2.24B | 354.84%579.4M | 1,839.51%690.01M | 71.00%573.14M | -1.86%395.48M | -50.66%471.1M | -170.47%-227.36M | -107.94%-39.67M | 53.49%335.17M | 568.67%402.96M |
Income tax | 258.45%728.14M | 485.11%183.52M | 7,827.32%233.86M | 92.48%189.58M | -18.86%121.19M | -36.49%203.14M | -161.16%-47.65M | -98.31%2.95M | 5.29%98.49M | 666.28%149.35M |
Net income | 463.46%1.51B | 320.29%395.88M | 1,170.37%456.16M | 62.06%383.56M | 8.15%274.29M | -57.80%267.97M | -173.44%-179.71M | -113.11%-42.62M | 89.61%236.68M | 525.49%253.61M |
Net income continuous operations | 463.46%1.51B | 320.29%395.88M | 1,170.36%456.16M | 62.06%383.56M | 8.15%274.29M | -57.80%267.97M | -173.44%-179.71M | -113.11%-42.62M | 89.61%236.68M | 525.49%253.61M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 463.46%1.51B | 320.29%395.88M | 1,170.37%456.16M | 62.06%383.56M | 8.15%274.29M | -57.80%267.97M | -173.44%-179.71M | -113.11%-42.62M | 89.61%236.68M | 525.49%253.61M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 463.46%1.51B | 320.29%395.88M | 1,170.37%456.16M | 62.06%383.56M | 8.15%274.29M | -57.80%267.97M | -173.44%-179.71M | -113.11%-42.62M | 89.61%236.68M | 525.49%253.61M |
Gross dividend payment | ||||||||||
Basic earnings per share | 463.42%198.38 | 320.29%52.01 | 1,170.36%59.94 | 62.03%50.39 | 8.16%36.04 | -57.80%35.21 | -173.44%-23.61 | -113.11%-5.6 | 89.63%31.1 | 525.54%33.32 |
Diluted earnings per share | 463.42%198.38 | 320.27%52.01 | 1,170.26%59.9345 | 62.04%50.39 | 8.16%36.04 | -57.80%35.21 | -173.44%-23.6116 | -113.11%-5.6 | 89.62%31.0973 | 525.54%33.32 |
Dividend per share | 0.00%15 | 0.00%15 | 0 | 0 | 0 | 0.00%15 | 0.00%15 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |